Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PTN Stock Forecast 2025-2026
$0.13
Current Price
$2.45M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PTN Price Targets
+5,284.6%
To High Target of $7.00
+5,284.6%
To Median Target of $7.00
+5,284.6%
To Low Target of $7.00
PTN Price Momentum
+30.0%
1 Week Change
-40.9%
1 Month Change
-93.5%
1 Year Change
-88.3%
Year-to-Date Change
-93.9%
From 52W High of $2.14
+271.4%
From 52W Low of $0.04
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Palatin (PTN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PTN and similar high-potential opportunities.
Latest PTN Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, PTN has a bullish consensus with a median price target of $7.00 (ranging from $7.00 to $7.00). Currently trading at $0.13, the median forecast implies a 5,284.6% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 5,284.6% upside. Conversely, the most conservative target is provided by Joseph Pantginis at HC Wainwright & Co., suggesting a 5,284.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PTN Analyst Ratings
1
Buy
0
Hold
0
Sell
PTN Price Target Range
Low
$7.00
Average
$7.00
High
$7.00
Current: $0.13
Latest PTN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PTN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 13, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $7.00 |
| Feb 7, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $17.00 |
| Dec 19, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Nov 25, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Nov 4, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Oct 31, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Oct 24, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Jun 20, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Jun 12, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| May 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| May 8, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| May 2, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Feb 28, 2024 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
| Feb 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Aug 10, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Aug 8, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Aug 7, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| May 30, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| May 9, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Mar 13, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 |
Palatin Technologies, Inc. (PTN) Competitors
The following stocks are similar to Palatin based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PTN
Palatin Technologies
mkt cap
2.45M
Palatin Technologies, Inc. (PTN) Financial Data
Palatin Technologies, Inc. has a market capitalization of $2.45M with a P/E ratio of -0.1x. The company generates $350,000 in trailing twelve-month revenue with a 97.8% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -8,684.2% and return on equity of +26,669.9%.
Valuation Metrics
Market Cap
$2.45M
Enterprise Value
$-611,669
P/E Ratio
-0.1x
PEG Ratio
0.1x
Price/Sales
7.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-8,684.2%
Net Margin
+97.8%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+100.8%
Current Ratio
0.4x
Debt/Equity
-0.1x
ROE
+26,669.9%
ROA
-212.7%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Palatin Technologies, Inc. (PTN) Business Model
About Palatin Technologies, Inc.
What They Do
Develops targeted therapeutics for various diseases.
Business Model
Palatin Technologies operates in the biopharmaceutical sector, focusing on developing receptor-specific therapeutics. The company generates revenue primarily through the commercialization of its lead product, Vyleesi, and aims to monetize its pipeline of drugs currently in various stages of clinical trials.
Additional Information
Founded in 1986 and based in Cranbury, New Jersey, Palatin is advancing multiple therapeutic candidates, including those targeting conditions like hypoactive sexual desire disorder and inflammatory bowel diseases. The company's ongoing clinical trials for PL9643 and PL8177 highlight its commitment to addressing unmet medical needs in the biopharmaceutical space.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
30
CEO
Dr. Carl Spana Ph.D.
Country
United States
IPO Year
1997
Website
palatin.comPalatin Technologies, Inc. (PTN) Latest News & Analysis
Latest News
Quick Summary
Palatin Technologies, Inc. will hold a teleconference today at 11:00 AM EST to discuss progress in its obesity and ocular programs, alongside financial results for Q3 2025.
Why It Matters
Palatin Technologies' advancements in obesity and ocular programs may enhance its product pipeline, potentially increasing market value and attracting investor interest in its financial performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Palatin Technologies' PL9588 shows promise as a dual-action glaucoma therapy, reducing intraocular pressure and offering neuroprotection, according to new preclinical data presented at ARVO 2025.
Why It Matters
Positive preclinical data for PL9588 could enhance Palatin Technologies' market position in glaucoma treatments, potentially boosting stock value and attracting investor interest in innovative therapies.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Palatin Technologies, Inc. announced a public offering of 76.67 million shares at $0.15 each, with new and existing institutional investors participating. The offering includes Series F, G, and H warrants.
Why It Matters
Palatin Technologies' public offering raises $11.5 million, signaling investor confidence and providing funds for development, which may enhance market positioning and future valuation.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Palatin Technologies plans to advance its obesity program with IND applications for new peptides and molecules by Q4 2025, and expects clinical data by H1 2026. It has a public offering of $11.5 million closing on May 8, 2025.
Why It Matters
Palatin Technologies' funding boosts its obesity program and strategic initiatives, potentially enhancing its market position and driving future growth, impacting investor confidence and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)
10 days ago
Quick Summary
NYSE American has initiated delisting proceedings for Palatin Technologies, Inc. (PTN) due to the company's common stock price not meeting listing standards.
Why It Matters
Delisting of Palatin Technologies (PTN) indicates financial instability, potentially leading to reduced investor confidence and declining stock value. This could impact liquidity and future funding opportunities.
Source: Business Wire
Market Sentiment:
Neutral
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice
10 days ago
Quick Summary
Palatin Technologies, Inc. received a notice from NYSE American about proceedings to delist its common stock. The company plans to request a review of this determination.
Why It Matters
Palatin's potential delisting from the NYSE could lead to reduced liquidity and investor confidence, impacting stock value and market perception significantly.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PTN Stock
What is Palatin Technologies, Inc.'s (PTN) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Palatin Technologies, Inc. (PTN) has a median price target of $7.00. The highest price target is $7.00 and the lowest is $7.00.
Is PTN stock a good investment in 2025?
According to current analyst ratings, PTN has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.13. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PTN stock?
Wall Street analysts predict PTN stock could reach $7.00 in the next 12 months. This represents a 5,284.6% increase from the current price of $0.13. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Palatin Technologies, Inc.'s business model?
Palatin Technologies operates in the biopharmaceutical sector, focusing on developing receptor-specific therapeutics. The company generates revenue primarily through the commercialization of its lead product, Vyleesi, and aims to monetize its pipeline of drugs currently in various stages of clinical trials.
What is the highest forecasted price for PTN Palatin Technologies, Inc.?
The highest price target for PTN is $7.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 5,284.6% increase from the current price of $0.13.
What is the lowest forecasted price for PTN Palatin Technologies, Inc.?
The lowest price target for PTN is $7.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 5,284.6% increase from the current price of $0.13.
What is the overall PTN consensus from analysts for Palatin Technologies, Inc.?
The overall analyst consensus for PTN is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are PTN stock price projections?
Stock price projections, including those for Palatin Technologies, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 18, 2025 9:50 AM UTC